Juxtafoveal Choroidal Neovascularization Associated with Retinitis Pigmentosa Treated with Intravitreal Bevacizumab

Abstract

Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.